Stephen Faraone

Last updated
Stephen V. Faraone
Born (1956-07-27) July 27, 1956 (age 68)
Babylon, New York, USA
NationalityAmerican
Alma mater State University of New York at Stony Brook (B.A.)
University of Iowa (Ph.D.)
Brown University (Internship & Post Doctoral Programs)
Known forResearch into the nature, causes and treatment of ADHD
AwardsCHADD Hall of Fame, Chancellor's Award for Excellence in Scholarship and Creative Activities from the State University of New York, Alumni Fellow status at the University of Iowa.
Scientific career
FieldsChild psychology and psychiatry
Institutions Harvard Medical School

Massachusetts General Hospital

State University of New York Upstate Medical University
Doctoral advisor Richard Hurtig, Ph.D.

Stephen Vincent Faraone (born July 27, 1956) [1] is an American psychologist who is a distinguished professor of psychiatry, physiology and neuroscience at SUNY Upstate Medical University and president of the World Federation of ADHD. [2] Involved in research since 1978, he is an expert on attention-deficit hyperactivity disorder (ADHD) and related disorders and is considered one of the most influential psychologists in the world. [3]

Contents

Education and career

Faraone graduated in 1978 from the State University of New York at Stony Brook with a BA in Psychology. He then went to the University of Iowa where he obtained his Master of Arts and Doctor of Philosophy. [4] Faraone completed a postdoctoral clinical psychology internship and a research fellowship at Brown University. [4]

After completing his post-doctoral fellowship at Brown, Faraone came to the Harvard Department of Psychiatry, where he began a career in psychiatric genetics. He first served as an instructor in 1985, and as an assistant professor in 1989. He was promoted to associate professor in 1993 and Full Professor in 2002. In 2004, he moved to SUNY Upstate Medical University where he is now Distinguished Professor of Psychiatry and of Neuroscience and Physiology. [5] He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital [6] and a lecturer at Harvard Medical School. Faraone has been principal investigator on several National Institutes of Health -funded grants studying the nature and causes of mental disorders in childhood. He is one of the world's leading authorities on the genetics of psychiatric disorders and has also made substantial contributions to research in psychopharmacology and research methodology. He led the International Consensus Statement on ADHD, [7] and heads The ADHD Evidence Project, which curates evidence-based information about ADHD. [8]

Faraone is a member of the European ADHD Guidelines Group (EAGG) and has founded the ADHD Molecular Genetics Network and the American Professional Society of ADHD and Related Disorders. [2] [9]

Awards and honors

Faraone has authored over 700 journal articles, [10] editorials, chapters, and books, and was the eighth-highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI). [11] In 2005, ISI determined him to be the second-highest cited author in the area of ADHD [12] and in 2007, he was the third most highly cited researcher in psychiatry [13] for the preceding decade. From 2014 to 2021 he has been listed as a highly cited researcher by Thomson Reuters/Clarivate Analytics. In 2019 and 2020, his citation metrics placed him in the top 0.01% of scientists across all fields. [14]

In 2002, Faraone was inducted into the CHADD Hall of Fame in recognition of outstanding achievement in medicine and education research on attention disorders. In 2004 and 2008, Faraone was elected vice president of the International Society of Psychiatric Genetics and in 2019 he received the Paul Hoch Award from the American Psychopathological Association. In 2008, he received the SUNY Upstate President's Award for Excellence and Leadership in Research. [15] In 2019 he was elected president of the World Federation of ADHD. [16] In 2022 he was elected to the Norwegian Academy of Science and Letters.

Research Funding and Financial Disclosures

Faraone's research has been funded by the U.S. National Institute of Health, the European Union and the following companies: Otsuka, Shire/Takeda, Ironshore, McNeil, Janssen and Supernus. He has received income or potential income from Aardvark, Rhodes, OnDosis, Oysta, Sky Therapeutics, AIMH, Tris, Otsuka, Arbor, Ironshore, KemPharm/Corium, Akili, Supernus, Shire/Takeda, Atentiv, Noven, Axsome, Johnson & Johnson/Kenvue and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. These disclosures are routinely reported in relevant publications. [17]

Books published

Related Research Articles

<span class="mw-page-title-main">Attention deficit hyperactivity disorder</span> Neurodevelopmental disorder

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by executive dysfunction occasioning symptoms of inattention, hyperactivity, impulsivity and emotional dysregulation that are excessive and pervasive, impairing in multiple contexts, and developmentally-inappropriate.

<span class="mw-page-title-main">Methylphenidate</span> Central nervous system stimulant

Methylphenidate, sold under the brand names Ritalin and Concerta among others, is a central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, narcolepsy. It may be taken by mouth or applied to the skin, and different formulations have varying durations of effect. For ADHD, the effectiveness of methylphenidate is comparable to atomoxetine but modestly lower than amphetamines, alleviating the executive functioning deficits of sustained attention, inhibition, working memory, reaction time and emotional self-regulation.

Lars Christopher Gillberg is a professor of child and adolescent psychiatry at Gothenburg University in Gothenburg, Sweden. He has been a visiting professor at the universities of Bergen, New York, Odense, St George's, San Francisco, and Glasgow and Strathclyde. Gillberg is the founding editor of the journal European Child & Adolescent Psychiatry.

<span class="mw-page-title-main">Peter Breggin</span> American psychiatrist

Peter Roger Breggin is an American psychiatrist and critic of shock treatment and psychiatric medication and COVID-19 response. In his books, he advocates replacing psychiatry's use of drugs and electroconvulsive therapy with psychotherapy, education, empathy, love, and broader human services.

Adult Attention Deficit Hyperactivity Disorder is the persistence of attention deficit hyperactivity disorder (ADHD) into adulthood. It is a neurodevelopmental disorder, meaning impairing symptoms must have been present in childhood, except for when ADHD occurs after traumatic brain injury. Specifically, multiple symptoms must be present before the age of 12, according to DSM-5 diagnostic criteria. The cutoff age of 12 is a change from the previous requirement of symptom onset, which was before the age of 7 in the DSM-IV. This was done to add flexibility in the diagnosis of adults. ADHD was previously thought to be a childhood disorder that improved with age, but recent research has disproved this. Approximately two-thirds of childhood cases of ADHD continue into adulthood, with varying degrees of symptom severity that change over time and continue to affect individuals with symptoms ranging from minor inconveniences to impairments in daily functioning.

<span class="mw-page-title-main">Institute of Psychiatry, Psychology and Neuroscience</span> Research institution in London, England

The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) is a centre for mental health and neuroscience research, education and training in Europe. It is dedicated to understanding, preventing and treating mental illness, neurological conditions, and other conditions that affect the brain. The IoPPN is a faculty of King's College London, England, and was previously known as the Institute of Psychiatry (IoP).

<span class="mw-page-title-main">Viloxazine</span> Medication used to treat ADHD

Viloxazine, sold under the brand name Qelbree among others, is a selective norepinephrine reuptake inhibitor (sNRI) medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken orally. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form, latterly with comparable effectiveness to atomoxetine and methylphenidate.

<span class="mw-page-title-main">Russell Barkley</span> American psychologist and author (born 1949)

Russell Alan BarkleyFAPA is a retired American clinical neuropsychologist who was a clinical professor of psychiatry at the VCU Medical Center until 2022 and president of Division 12 of the American Psychological Association (APA) and of the International Society for Research in Child and Adolescent Psychopathology. Involved in research since 1973 and a licensed psychologist since 1977, he is an expert on attention-deficit hyperactivity disorder (ADHD) and has devoted much of his scientific career to studying ADHD and related fields like childhood defiance. He proposed the renaming of sluggish cognitive tempo (SCT) to cognitive disengagement syndrome (CDS).

Attention deficit hyperactivity disorder predominantly inattentive, is one of the three presentations of attention deficit hyperactivity disorder (ADHD). In 1987–1994, there were no subtypes or presentations and thus it was not distinguished from hyperactive ADHD in the Diagnostic and Statistical Manual (DSM-III-R). In DSM-5, subtypes were discarded and reclassified as presentations of the same disorder that change over time.

<span class="mw-page-title-main">Attention deficit hyperactivity disorder controversies</span> Controversies surrounding the topic of ADHDs nature, diagnosis, and treatment

Despite the scientifically well-established nature of attention deficit hyperactivity disorder (ADHD), its diagnosis, and its treatment, each of these has been controversial since the 1970s. The controversies involve clinicians, teachers, policymakers, parents, and the media. Positions range from the view that ADHD is within the normal range of behavior to the hypothesis that ADHD is a genetic condition. Other areas of controversy include the use of stimulant medications in children, the method of diagnosis, and the possibility of overdiagnosis. In 2009, the National Institute for Health and Care Excellence, while acknowledging the controversy, stated that the current treatments and methods of diagnosis are based on the dominant view of the academic literature.

Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD. Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training, neurofeedback, neurostimulation, physical exercise, nutrition and supplements, integrative medicine, parent support, and school interventions. Based on two 2024 systematic reviews of the literature, FDA-approved medications and to a lesser extent psychosocial interventions have been shown to improve core ADHD symptoms compared to control groups.

Joseph Biederman was an American academic psychiatrist. He was Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital and a professor of psychiatry at Harvard Medical School.

The International Society of Psychiatric Genetics (ISPG) is a learned society that aims to "promote and facilitate research in the genetics of psychiatric disorders, substance use disorders and allied traits". To this end, among other things, it organizes an annual "World Congress of Psychiatric Genetics".

The following outline is provided as an overview of and topical guide to psychiatry:

Jeffery Halperin is a psychology professor at Queens College, City University of New York (CUNY) and a neuropsychology doctoral faculty member at the CUNY Graduate Center since 1989.

Psychiatry is, and has historically been, viewed as controversial by those under its care, as well as sociologists and psychiatrists themselves. There are a variety of reasons cited for this controversy, including the subjectivity of diagnosis, the use of diagnosis and treatment for social and political control including detaining citizens and treating them without consent, the side effects of treatments such as electroconvulsive therapy, antipsychotics and historical procedures like the lobotomy and other forms of psychosurgery or insulin shock therapy, and the history of racism within the profession in the United States.

The Child Mania Rating Scales (CMRS) is a 21-item diagnostic screening measure designed to identify symptoms of mania in children and adolescents aged 9–17 using diagnostic criteria from the DSM-IV, developed by Pavuluri and colleagues. There is also a 10-item short form. The measure assesses the child's mood and behavior symptoms, asking parents or teachers to rate how often the symptoms have caused a problem for the youth in the past month. Clinical studies have found the CMRS to be reliable and valid when completed by parents in the assessment of children's bipolar symptoms. The CMRS also can differentiate cases of pediatric bipolar disorder from those with ADHD or no disorder, as well as delineating bipolar subtypes. A meta-analysis comparing the different rating scales available found that the CMRS was one of the best performing scales in terms of telling cases with bipolar disorder apart from other clinical diagnoses. The CMRS has also been found to provide a reliable and valid assessment of symptoms longitudinally over the course of treatment. The combination of showing good reliability and validity across multiple samples and clinical settings, along with being free and brief to score, make the CMRS a promising tool, especially since most other checklists available for youths do not assess manic symptoms.

Ming Tso Tsuang is an American psychiatrist and Distinguished Professor of Psychiatry at the University of California, San Diego. He is considered a pioneering researcher in the genetic epidemiology of schizophrenia and other severe mental disorders. Tsuang has authored and co-authored more than 600 publications and serves as founding and senior editor of the American Journal of Medical Genetics Part B.

René Sylvain Kahn is a neuropsychiatrist and the Esther and Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai in the United States, a position he has held since 2017. He previously served as Professor of Psychiatry and Director of the Brain Center Rudolf Magnus at the University Medical Center Utrecht in the Netherlands. Kahn is recognized for his research on the neurobiology of schizophrenia. He served as a former president of the Schizophrenia International Research Society and was elected to the Royal Netherlands Academy of Arts and Sciences in 2009. He received the Neuropsychopharmacology Award from the European College of Neuropsychopharmacology in 2014.

<span class="mw-page-title-main">Jan K. Buitelaar</span> Dutch doctor, author and academic

Jan K. Buitelaar is a Dutch medical doctor, psychiatrist, author, and academic. He is a professor of psychiatry and child and adolescent psychiatry at Radboud University Medical Centre and former Head of Child and Adolescent Psychiatry at Karakter Child and Adolescent Psychiatry.

References

  1. ↑ "Stephen Faraone CV" (PDF). SUNY Upstate. Archived (PDF) from the original on 7 February 2019. Retrieved 4 February 2019.
  2. 1 2 "Faculty Profile | Psychiatry | SUNY Upstate".
  3. ↑ "SUNY Upstate professor named 80th best scientist in the world | Upstate News | SUNY Upstate Medical University". www.upstate.edu. Archived from the original on 2024-03-26. Retrieved 2024-03-26.
  4. 1 2 "Faculty | Psychiatry | SUNY Upstate". Archived from the original on 2008-06-28. Retrieved 2008-10-21.
  5. ↑ "Faculty:Psychiatry:SUNY Upstate Medical University". Archived from the original on 2009-04-27. Retrieved 2009-05-10.
  6. ↑ "About Our Department: Steve Faraone, PhD". Archived from the original on June 27, 2008. Retrieved 2009-05-10.
  7. ↑ "International Consensus Statement". www.adhdevidence.org. Archived from the original on 2024-06-14. Retrieved 2024-07-02.
  8. ↑ "ADHD Evidence Project". www.adhdevidence.org. Archived from the original on 2024-07-11. Retrieved 2024-07-02.
  9. ↑ "Members – EUNETHYDIS" . Retrieved 2024-07-24.
  10. ↑ "Faraone S[Author] - Search Results - PubMed".
  11. ↑ Science, 2000, Vol 288, pg 959
  12. ↑ An Interview with Dr. Stephen Faraone
  13. ↑ "The Most-Cited Researchers in Psychiatry/Psychology
  14. ↑ Ioannidis, John P. A.; Baas, Jeroen; Klavans, Richard; Boyack, Kevin W. (2019-08-12). "A standardized citation metrics author database annotated for scientific field". PLOS Biology. 17 (8): e3000384. doi: 10.1371/journal.pbio.3000384 . ISSN   1545-7885. PMC   6699798 . PMID   31404057.
  15. ↑ "Stephen Faraone". SUNY Upstate. Archived from the original on 9 November 2019. Retrieved 4 February 2019.
  16. ↑ "Board of the ADHD World Federation". www.adhd-federation.org. Archived from the original on 2021-01-26. Retrieved 2020-12-16.
  17. ↑ "2022 APSARD DISCLOSURE REPORT" (PDF). Archived (PDF) from the original on 2023-01-17. Retrieved 2023-01-17.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.